Warren Street Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$891K Buy
3,541
+77
+2% +$16.6K 0.2% 49
2026
Q1
$753K Buy
3,464
+81
+2% +$18K 0.19% 46
2025
Q4
$773K Sell
3,383
-251
-7% -$57.2K 0.22% 43
2025
Q3
$841K Buy
3,634
+174
+5% +$35.4K 0.25% 45
2025
Q2
$642K Sell
3,460
-53
-2% -$9.85K 0.21% 54
2025
Q1
$736K Buy
3,513
+469
+15% +$91.2K 0.29% 45
2024
Q4
$541K Buy
3,044
+1,006
+49% +$185K 0.22% 53
2024
Q3
$402K Buy
2,038
+192
+10% +$35.8K 0.17% 69
2024
Q2
$317K Buy
1,846
+206
+13% +$34.1K 0.16% 75
2024
Q1
$299K Buy
1,640
+107
+7% +$18.4K 0.15% 76
2023
Q4
$238K Buy
+1,533
New +$223K 0.13% 77

Other funds holding ABBV

Warren Street Wealth Advisors's ABBV Position: Q2 2026 in Review

Warren Street Wealth Advisors increased its AbbVie (ABBV) stake by 2.2% in Q2 2026, buying an estimated $16.6K and bringing the position to 3,541 shares worth $891K. The position accounts for 0.2% of the portfolio, ranked #49.

Warren Street Wealth Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 2,236 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Warren Street Wealth Advisors held 3,541 shares of AbbVie worth $891K as of Q2 2026.
  • Warren Street Wealth Advisors bought 77 AbbVie shares in Q2 2026, an estimated $16.6K.
  • AbbVie made up 0.2% of Warren Street Wealth Advisors's portfolio in Q2 2026, its #49 holding.
  • Warren Street Wealth Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 2,236 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Warren Street Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.